Clinical trials: Covid19- Coronavirus- Sars-cov-2
COVID-19 Infection
Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)
This study investigates a new diagnostic test in detecting SARS-CoV-2, the virus that causes the disease COVID-19. This may help to improve testing for COVID-19.
- Trial name
- END CoV-2 (NCT04513990)
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Covid19
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for…
- Trial name
- NCT04712279
- Testing
- Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Hydroxychloroquine
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Corpometria Institute
COVID-19
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05925127)
- Testing
- NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg)
- Where
- 50 sites in United States
- Volunteers
- 994 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation
This is the first-in-human phase 1/2a trial of the inhaled administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631705
- Testing
- DZIF-10c
- Where
- 6 sites in Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Cologne
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
SARS-CoV-2, COVID-19
Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3)
The purpose of this research is to gather information to answer questions about the Coronavirus Disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- EPIC3 (NCT05764083)
- Where
- United States
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2
Background: Background: Testing with antigen-detecting rapid diagnostic tests (Ag-RDTs), including in asymptomatic individuals, has the potential to promptly identify more Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT05458557
- Testing
- Rapid Antigen Testing
- Where
- Kenya
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Anxiety, Stress
Assessment of Stress and Associated Factors Among Young Adults During the COVID-19 Pandemic
Since the onset of COVID-19, studies conducted on the general population have shown an increase in the use of antidepressants and anxiolytics, a rise in domestic violence, and heightened demand for peri-urban housing offering…
- Conditions
- Anxiety, Stress, COVID - 19
- Trial name
- JADESTRESS (NCT07845396)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 1,322 people, healthy volunteers welcome
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
SARS-CoV-2 Infection, Covid19
Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers
With the unprecedented morbidity of the COVID-19 pandemic, the vaccine effectiveness needs to be assessed across diverse populations.
- Trial name
- NCT04795414
- Testing
- SARS-CoV-2 Vaccine(Vero Cell), Inactivated
- Where
- China
- Volunteers
- 1,370 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
COVID 19, Inflammatory Status
FOUND - Ancillary Study to Smile Protocol NCT03654105
During the current pandemic, in Italy the majority of asymptomatic or pauci-symptomatic COVID-19 cases were not identified nor diagnosed and this fact caused a decrease in the effectiveness of the various containment measures…
- Trial name
- FOUND (NCT04441814)
- Where
- Italy
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
COVID 19
Impact of Cryopreservation Methods on Post-Thaw SARS-CoV-2 in Semen Samples
Cryopreservation of seminal fluid or spermatozoa from epididymary and testicular retrieval represents a crucial tool in managing conditions of permanent or temporary infertility, as well as in cases of secretory and excretory…
- Trial name
- SEM-COV-19 (NCT06703723)
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Hepatic Impairment
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted…
- Trial name
- NCT05005312
- Testing
- PF-07321332, Ritonavir
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
Covid-19 Virtual Recovery Study
The purpose of this study is to determine the effects of respiratory muscle training (RMT) and nasal breathing on patients who have been infected with the SARS-CoV2 virus and continue to have lingering symptoms.
- Trial name
- NCT04950725
- Testing
- Strength RMT, Strength RMT and nasal breathing, Endurance RMT
- Where
- United States
- Volunteers
- 2,268 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19, Immunologic Factors
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.
A two-stage trial will involve healthy volunteers. The first stage is open trial, and the second stage is a double-blind trial with randomization of volunteers into three groups.
- Conditions
- COVID-19, Immunologic Factors, Coronavirus Infections, Respiratory Tract Infections
- Trial name
- NCT05156723
- Testing
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Where
- 3 sites in Russia
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Covid19
COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020
The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been…
- Trial name
- NCT04723290
- Testing
- Serological tests for SARS Cov-2
- Where
- Belgium
- Volunteers
- 2,817 people, healthy volunteers welcome
- Sponsor
- Grand Hôpital de Charleroi
SARS CoV 2 Infection
Rutgers Pilot for PREDICT- Patient POC Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral antigen using a point-of-care (POC) Rapid…
- Trial name
- NCT05612724
- Testing
- Testing for SARS CoV2 Antigen
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.